Hemogenyx Pharmaceuticals (HEMO) is a preclinical-stage biopharmaceutical company focused on the development of its novel treatments which aim to transform the bone marrow transplantation procedure (BMT). A BMT is a potential life-saver for late-stage patients with blood diseases such as leukemia and lymphoma.
01 Mar 2018
Hemogenyx Pharmaceuticals - Initiation of Coverage
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Hemogenyx Pharmaceuticals - Initiation of Coverage
HemoGenyx Pharmaceuticals Plc (HEMO:LON) | 1.6 0 (-1.8%) | Mkt Cap: 22.0m
- Published:
01 Mar 2018 -
Author:
Richard Gill, CFA -
Pages:
24
Hemogenyx Pharmaceuticals (HEMO) is a preclinical-stage biopharmaceutical company focused on the development of its novel treatments which aim to transform the bone marrow transplantation procedure (BMT). A BMT is a potential life-saver for late-stage patients with blood diseases such as leukemia and lymphoma.